We formulated the “Big Bang” model of tumour growth in which the cancer grows as a single expansion populated by a large number of intermixed clones. We used the term because this model implies that a signature of the early origins of the malignancy can be recovered from the present day tumour, in the same way that the Cosmic Microwave Background represents a signature of the birth of our Universe.
The take home message here is that this is a review article, not a systematic review, and as such, I wouldn’t have even included in as part of my literature reviews. This doesn’t change anything much for me at all. Regardless of what the many, many media stories covering it say.
Dépistage, diagnostic et pronostic
In short, the 17-member independent panel said that it could not determine — after reviewing thousands of research papers and studies from around the world — whether the benefits of screening outweighed the potential for harm if unnecessary or excessive procedures were performed.
In a shift from the 2009 guidelines, the task force has eliminated recommendations that patients do self-exams.
The American Cancer Society does not currently recommend annual skin exams by a clinician. The ACS does recommend that adults become familiar with the appearance of the skin, be alert for new or changing skin growths, and seek prompt evaluation by a physician if a change is observed.
Liquid Biopsies in Transforming Cancer Patient Care: AACR Partners with FDA in Moving the Needle [AACR]A major focus of the workshop was to build on the application of cell-free DNA (cfDNA) technologies for lung cancer.
"Many clinicians claim the benefits of robotic technology lead to improved quality of life and oncological outcomes. Our randomised trial, the first of its kind, found no statistical difference in quality of life outcomes between the two groups at 12 weeks follow up."
Cambridge, MA-based Tokai said that an independent data monitoring committee instructed the company to stop the big Phase 3 trial of its prospective prostate cancer drug, galeterone, early because the study was likely to fail.
Bristol-Myers' Opdivo front-and-center in yet another cancer-fighting team-up, this time with Janssen [FiercePharma]The deal is part of an ongoing space race in immuno-oncology, as drugmakers anticipate a new era of cancer-fighting combination regimens and strike partnership deals in hopes of hitting upon the most effective cocktails.
Lutte contre les cancers
The European Research Council has begun to evaluate the impact of its grants; others should do the same.
The pilot evaluation rated projects that were among the first to be funded by the council, mostly in 2007 and 2008. It assigned eight projects each to 25 three-person expert groups.
And, as the answers to cancer’s challenges becomes even more of a global challenge, we’ll need more collaboration with partners in other countries in the years to come, not less.